First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
Condition(s):Gastrointestinal Neuroendocrine CarcinomaLast Updated:October 6, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Gastrointestinal Neuroendocrine CarcinomaLast Updated:October 6, 2023Recruiting
Condition(s):Multiple MyelomaLast Updated:April 25, 2023Recruiting
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:March 1, 2016Unknown status
Condition(s):Helicobacter Pylori InfectionLast Updated:June 12, 2017Unknown status
Condition(s):Breast NeoplasmLast Updated:July 24, 2012Unknown status
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:April 26, 2018Completed
Condition(s):Hepatocellular CarcinomaLast Updated:February 1, 2022Terminated
Condition(s):Metastatic Colorectal CancerLast Updated:October 26, 2022Recruiting
Condition(s):Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction AdenocarcinomaLast Updated:May 17, 2021Recruiting
Condition(s):Renal Cell CarcinomaLast Updated:January 11, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.